WA
BBIO icon

WPG Advisers’s BridgeBio Pharma BBIO Stock Holding History

WPG Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.56K Sell
115
-46
-29% -$3.22K 0.01% 817
2026
Q1 		$12K Buy
161
+4
+3% +$290 0.01% 616
2025
Q4 		$12K Buy
157
+145
+1,208% +$9.52K 0.01% 652
2025
Q3 		$623 Buy
+12
New +$585 ﹤0.01% 1335

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

WPG Advisers's BBIO Position: Q2 2026 in Review

WPG Advisers reduced its BridgeBio Pharma (BBIO) stake by 29% in Q2 2026, selling an estimated $3.22K and leaving 115 shares worth $8.56K. The position accounts for 0.01% of the portfolio, ranked #817.

WPG Advisers first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $12K in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • WPG Advisers held 115 shares of BridgeBio Pharma worth $8.56K as of Q2 2026.
  • WPG Advisers sold 46 BridgeBio Pharma shares in Q2 2026, an estimated $3.22K.
  • BridgeBio Pharma made up 0.01% of WPG Advisers's portfolio in Q2 2026, its #817 holding.
  • WPG Advisers first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • WPG Advisers's BridgeBio Pharma position peaked at $12K in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.